BAX 499

Drug Profile

BAX 499

Alternative Names: Anti-TFPI aptamer; ARC19499

Latest Information Update: 15 Oct 2015

Price : $50

At a glance

  • Originator Archemix Corporation
  • Developer Baxalta
  • Class Antihaemorrhagics; Coagulants; Oligonucleotides; Peptide aptamers
  • Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haemophilia

Most Recent Events

  • 27 Jul 2011 Interim pharmacodynamics data from a preclinical study in Haemophilia released by Baxter International
  • 21 Nov 2010 Baxter International enters into a definitive agreement to acquire all of Archemix's haemophilia-related assets
  • 31 Aug 2010 Phase-I clinical trials in Haemophilia in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top